Intra-Cellular Reports the Expansion of Pipeline with the Addition of ITI-1284

 Intra-Cellular Reports the Expansion of Pipeline with the Addition of ITI-1284

Intra-Cellular Reports the Expansion of Pipeline with the Addition of ITI-1284

Shots:

  • Following the completion of a P-I program, the company plans to initiate P- II studies to evaluate ITI-1284 ODT-SL for the treatment of behavioral disturbances in dementia, dementia-related psychosis and certain depressive disorders in the elderly
  • The P-I single and multiple ascending dose studies in healthy volunteers including elderly subjects aged >65yrs. evaluated the safety, tolerability and PK of ITI-1284 and reported no SAEs in either age group
  • TI-1284 is a deuterated form of lumateperone, delivered sublingually as an ODT-SL and offer pharmacologic benefits and ease of use for patients, particularly in elderly populations

Click here ­to­ read full press release/ article | Ref: GlobeNewswire | Image: The Science of Parkinson’s

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post